abstract: BACKGROUND: The prognostic role of @entity7457 ( @entity7457 ) expression in @entity2 has been assessed but with inconsistent results. The present study aimed to evaluate the prognostic value of @entity10922 expression in advanced non-squamous @entity1149 ( @entity1149 ). MATERIALS AND METHODS: In this retrospective study, @entity1 with stage IIIB-IV non-squamous @entity1149 were enrolled. Progression free survival (PFS) and @entity1349 ( @entity1349 ) were assessed according to @entity10922 expression status, age categories ( <=60 vs >60 years), gender, performance status (PS) (0-2 vs 3-4), type of 1st line chemotherapy (pemetrexed containing vs others) and @entity470 status. RESULTS: A total of 120 @entity1 were included. In univariate analysis, PFS was improved in @entity1 with PS 0-2 (7.0 vs 2.0 months, p=0.002) and those who received pemetrexed-containing chemotherapy (9.2 vs 5.8 months, p=0.004). @entity1349 was improved in female @entity1 (23.0 vs 8.7 months, p<0.0001), PS 0-2 (14.4 vs 2.0 months, p<0.0001), those with pemetrexed-containing chemotherapy (17.0 vs 11.0 months, p=0.019), @entity10922 -positive (12.8 vs 5.8 months, p=0.011) and @entity470 - mutant @entity1 (23.0 vs 11.7 months, p=0.006). In multivariate analysis, male gender (HR=2.34, p=0.025) and non-pemetrexed containing therapy (HR=2.24, p=0.022) were independent predictors of worse PFS. Wild @entity470 status (HR=2.49, p=0.015) and male gender (HR=2.78, p=0.008) were predictors of worse @entity1349 . CONCLUSIONS: Pemetrexed-containing therapy significantly improved PFS while @entity1349 was improved in @entity470 mutant @entity1 . Female @entity1 had better PFS and @entity1349 . @entity10922 expression was not a prognostic marker in advanced non-squamous @entity1149 .

title: XXXX expression in advanced @entity1149 : impact on survival outcome.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity1149 :: ('MESH:D002289', 'Disease') :: ['NSCLC', 'non-small cell lung cancer']

entities_list: @entity2 :: ('MESH:D008175', 'Disease') :: ['lung cancer']

entities_list: @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']

entities_list: @entity7457 :: ('7080', 'Gene') :: ['TTF-1', 'thyroid transcription factor-1']

answer: @entity7457 :: (7080,Gene) :: ['Thyroid transcription factor-1']


abstract: PURPOSE: Occupational and environmental exposures remain important modifiable risk factors of public health. Existing cohort studies are often limited by the level of detail of data collected on these factors and health. It is also often assumed that the more healthy group is over-represented in cohort studies, which is of concern for their external validity. In this cohort profile, we describe how we set up the population-based Occupational and Environmental Health Cohort Study ( @entity66073 ) to longitudinally study occupational and @entity66 and well-being from a multidisciplinary and life course point of view. Reviewed by the Medical Ethics Research Committee of the University Medical Center Utrecht (protocol 10-268/C). All cohort members participate voluntarily and gave informed consent prior to their inclusion. @entity1 : 14,829 adult cohort members (16% of those invited) consented and filled in the online baseline questionnaire. Determinants include chemical, biological, physical (eg, electromagnetic fields), and psychosocial factors. Priority health outcomes include @entity5 , @entity65 and non-specific symptoms. Owing to the recruitment strategy via general practitioners of an established network, we also collect longitudinal data registered in their electronic medical records including symptoms, diagnosis and treatments. Besides the advantage of health outcomes that cannot be easily captured longitudinally by other means, this created a unique opportunity to assess health-related participation bias by comparing general practitioner-registered prevalence rates in the cohort and its source population. FINDINGS TO DATE: We found no indications of such a systematic bias. The major assets of the @entity66073 approach are its detailed occupational and environmental determinants in combination with the longitudinal health data registered in general practice besides linkage to @entity5 and mortality registries and self-reported health. FUTURE PLANS: We are now in the phase of prospective follow-up, with the aim of continuing this for as long as possible (20+ years), pending future funding. Findings will be disseminated through scientific conferences and peer-reviewed journals, and through newsletters and the project website to @entity1 , stakeholders and the wider public.

title: The population-based Occupational and Environmental Health Prospective Cohort Study ( XXXX ) in The Netherlands.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'PARTICIPANTS']

entities_list: @entity66 :: ('MESH:D004194', 'Disease') :: ['environmental determinants of diseases']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer']

entities_list: @entity65 :: ('MESH:D002318', 'Disease') :: ['neurological, cardiovascular and respiratory diseases']

answer: @entity66073 :: (57463,Gene) :: ['AMIGO']


abstract: Importance: @entity28502 ( @entity28502 ) is associated with a wide variety of @entity5 ; nevertheless, @entity259 has not been evaluated in this syndrome. Due to the Brazilian founder mutation @entity28503 , some @entity5 that have not been described in the classic @entity28502 have been observed in a higher-than-expected prevalence in Brazil. Objective: To determine the frequency of @entity259 in Brazilian carriers of a founder @entity876 @entity28503 mutation. Design, Setting, and @entity1 : We reviewed medical records of @entity1 with @entity28502 with germline @entity876 @entity28503 mutation. For a better understanding of the correlation between @entity259 and @entity28502 , @entity5 profile data of Brazilian carriers were analyzed. We included data from 193 @entity1 with @entity28502 with the @entity876 @entity28503 mutation from the database of the Department of Oncogenetics from the A.C. Camargo @entity5 Center. Main Outcomes and Measures: @entity259 found in this population were reviewed with regard to age at diagnosis, sex, histologic subtype, and other @entity5 presented by these @entity1 . Results: Overall, 101 of 193 @entity876 @entity28503 mutation carriers with @entity28502 from 58 families were @entity5 affected and, among them, @entity259 presented a prevalence of 10.9% (3 @entity1 and 8 @entity1 ). The mean age at diagnosis was 44 years (median [SD], 43 [14.77] years). All the cases were histologically classified as @entity1377 , with 2 of them exhibiting follicular variant. The most common other @entity5 in the @entity1 with @entity259 were @entity0 (5 @entity1 ) and soft-tissue @entity242 (2 @entity1 ). Conclusions and Relevance: @entity259 may be associated with the Brazilian founder @entity876 @entity28503 mutation. Knowledge about this genotype/phenotype correlation is relevant to adjusting the @entity28502 screening recommendations to these specific carriers.

title: Frequency of @entity259 in Brazilian XXXX @entity28503 Carriers With @entity28502 .

entities_list: @entity1 :: ('9606', 'Species') :: ['men', 'women', 'patients', 'Participants']

entities_list: @entity1377 :: ('MESH:D002291', 'Disease') :: ['papillary carcinomas']

entities_list: @entity28502 :: ('MESH:D016864', 'Disease') :: ['LFS', 'Li Fraumeni syndrome']

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancers', 'cancer', 'Cancer', 'tumors']

entities_list: @entity259 :: ('MESH:D013964', 'Disease') :: ['thyroid carcinoma', 'Thyroid carcinoma', 'Thyroid tumors']

answer: @entity876 :: (7157,Gene) :: ['TP53']


abstract: BACKGROUND: @entity1 with @entity161 have substantially reduced subjective well-being (SW) compared to healthy individuals. It has been suggested that diminished SW may be related to deficits in the neural processing of reward but this has not been shown directly. We hypothesized that, in @entity161 , @entity392 would be associated with attenuated reward-related activation in the reward network. METHOD: Twenty @entity1 with @entity161 with a range of SW underwent a functional magnetic resonance imaging (fMRI) reward task. The brain activity underlying reward anticipation and outcome in @entity161 was examined and compared to that of 12 healthy @entity1 using a full factorial analysis. Region of interest (ROI) analyses of areas within the reward network and whole-brain analyses were conducted to reveal neural correlates of SW. RESULTS: Reward-related neural activity in @entity161 was not significantly different from that of healthy @entity1 ; however, the @entity1 with @entity161 showed significantly diminished SW. Both ROI and whole-brain analyses confirmed that SW scores in the @entity1 correlated significantly with activity, specifically in the dorsal anterior cingulate cortex ( @entity21839 ), during both reward anticipation and reward outcome. This association was not seen in the healthy @entity1 . CONCLUSIONS: In @entity1 with @entity161 , reduced activation of the @entity21839 during multiple aspects of reward processing is associated with @entity392 . As the @entity21839 has been widely linked to coupling of reward and action, and the link to SW is apparent over anticipation and outcome, these findings suggest that @entity51 in @entity161 may be attributable to reduced integration of environmental rewarding cues, motivated behaviour and reward outcome.

title: Impaired subjective well-being in XXXX is associated with reduced anterior cingulate activity during reward processing.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Patients', 'patients']

entities_list: @entity51 :: ('MESH:D009461', 'Disease') :: ['SW deficits']

entities_list: @entity161 :: ('MESH:D012559', 'Disease') :: ['schizophrenia']

answer: @entity161 :: (MESH:D012559,Disease) :: ['schizophrenia']


abstract: PURPOSE: To characterize and quantitatively assess focal radiation reactions in the liver after stereotactic single-dose radiotherapy for @entity409 . METHODS AND MATERIALS: A total of 131 multiphasic CT scans were performed in 36 @entity1 before and after stereotactic radiotherapy for @entity96 . The examination protocol included a nonenhanced scan and contrast-enhanced scans at different times after contrast injection. The volume of the reaction was determined in each scan and the threshold dose calculated using the dose-volume histogram of the treatment plan. RESULTS: Every @entity1 showed a focal radiation reaction on at least one follow-up examination. In 74% of the posttherapeutic scans, a sharply demarcated hypodense area surrounded the treated @entity5 in the nonenhanced scans. The reaction occurred at a median of 1.8 months (range 1.2-4.6) after radiotherapy. The median threshold dose was 13.7 Gy (range 8.9-19.2). The threshold dose strongly correlated with the time of detection after therapy (r = 0.7). Radiologically, three reaction types were found on the enhanced scans: type 1, portal-venous phase: hypodense and late phase: isodense; type 2, portal-venous phase: hypodense and late phase: hyperdense; and type 3, portal-venous phase: isodense/hyperdense and late phase: hyperdense. Type 1 or 2 reactions were observed significantly earlier than type 3 (p <0.05). The median threshold dose for type 1 or 2 reactions was significantly lower than for type 3 (p <0.05). The reaction volume decreased with longer follow-up (2-4 months: median 40% of initial volume). The reaction types shifted with follow-up: 58% were of type 1 at the initial manifestation and 58% were of type 3 at the next examination thereafter. CONCLUSION: A focal radiation reaction occurs after stereotactic single-dose therapy in the liver. The volume of the reaction decreases and changes its radiologic appearance during follow-up. This reaction has to be differentiated from recurrent @entity5 .

title: Assessment of focal liver reaction by multiphasic CT after stereotactic single-dose radiotherapy of XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity409 :: ('MESH:D008107', 'Disease') :: ['liver malignancies']

entities_list: @entity96 :: ('MESH:D008113', 'Disease') :: ['liver tumors']

answer: @entity96 :: (MESH:D008113,Disease) :: ['liver tumors']


abstract: Thirteen cases of @entity1 with the @entity8579 were reviewed. In two cases the diagnosis was made by incidental biopsy of small liver nodules at operation for peptic @entity1066 . Seven @entity1 had gastric secretory tests which showed a basal acid output to maximum acid output ratio of more than 65 percent. Five @entity1 had bao:mao ratios less than 50 percent.A 30-month interval between incidental discovery of @entity5 and clinically evident disease was observed in two @entity1 . Recurrence of symptoms after excision of @entity5 was noted after a similar interval in another case. Serum @entity8243 levels, before total gastrectomy, were elevated in all cases. The lowest preoperative level in this series of @entity1 was 550 picograms per ml (normal 100 to 150 picograms). They were diagnostic in two @entity1 with normal gastric secretory studies. The levels fell to normal following total gastrectomy in six @entity1 . Two @entity1 still had elevated levels five years and 14 years after total gastrectomy. One was discovered to have a @entity3243 with @entity2741 . Total gastrectomy was curative in all the @entity1 with the @entity8579 ; lesser operations were not.

title: Acid secretion and serum @entity8243 levels in the XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity2741 :: ('MESH:D006934', 'Disease') :: ['hypercalcemia']

entities_list: @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcer disease']

entities_list: @entity8579 :: ('MESH:D015043', 'Disease') :: ['Zollinger-Ellison syndrome']

entities_list: @entity3243 :: ('MESH:D010282', 'Disease') :: ['parathyroid adenoma']

answer: @entity8579 :: (MESH:D015043,Disease) :: ['Zollinger-Ellison syndrome']


abstract: BACKGROUND AND PURPOSE: Despite extensive use of MR imaging to provide markers of @entity15 ( @entity15 ) activity and accumulated disease burden, the magnitude of the relationship between clinical and MR findings is still debated. Using data from the European/Canadian glatiramer @entity598 (GA) trial, we investigated short-term correlations between clinical and MR measures of disease activity in @entity1 with @entity3780 ( @entity3780 ). METHODS: In a 9-month, double-blinded, placebo-controlled study, 239 @entity1 with @entity3780 were randomly assigned to receive 20 mg GA (n = 119) or placebo (n = 120). Clinical assessment included monthly neurologic examinations with Expanded Disability Status Scale scoring and visits for symptoms suggestive of relapse. Dual-echo T2-weighted and pre- and postcontrast T1-weighted brain MR images were obtained at baseline and monthly during follow-up. Contrast-enhancing and new T2-hyperintense lesions were counted, and total T2-hyperintense and T1-hypointense lesion volumes were measured. RESULTS: Significant univariate correlations were found between the number of relapses during the study period and the number of enhancing lesions at baseline (r = 0.25) and during follow-up (r = 0.30) in the study population as a whole. Multivariable analysis showed that two independent factors were more strongly correlated with relapse frequency: the number of relapses during the 2 years before entry and the number of on-trial enhancing lesions, in the whole study population and in the placebo group. CONCLUSION: In @entity3780 , MR imaging measures of inflammatory activity are modestly but significantly correlated with the occurrence of clinical attacks over the short term. Clinical and MR imaging assessment can provide complementary outcome measures for @entity3780 trials.

title: Short-term correlations between clinical and MR imaging findings in relapsing-remitting XXXX .

entities_list: @entity3780 :: ('MESH:D020529', 'Disease') :: ['relapsing-remitting MS', 'RRMS']

entities_list: @entity15 :: ('MESH:D009103', 'Disease') :: ['MS', 'multiple sclerosis']

entities_list: @entity598 :: ('CHEBI:47622', 'Chemical') :: ['acetate']

answer: @entity15 :: (MESH:D009103,Disease) :: ['multiple sclerosis']


abstract: BACKGROUND: @entity293 ( @entity293 ) in young @entity1 carries the risk of parenchymal damage and sequelae. The location of the @entity281 within the urinary tract influences decisions regarding both therapeutics and follow-up. Because clinical features and laboratory markers of @entity281 at an early age are not specific, it is difficult to make a distinction between lower @entity293 and @entity2885 . @entity1904 (PCT) has been studied as a marker of severe @entity2348 . The aim of this study was to test the usefulness of PCT concentration in serum to distinguish between uncomplicated @entity293 and severe @entity2885 with @entity8 . METHODS: PCT was measured by immunoluminometric assay in serum samples from @entity1 with microbiologically documented @entity281 . Severe renal involvement was assessed by @entity29582 gammagraphy done 5 to 6 months after the episode to check for the presence of parenchymal scars. @entity1851 ( @entity1851 ) and leukocyte count were also measured. RESULTS: PCT at presentation showed a significant correlation (P < 0.001) with the presence of @entity8 in @entity1 with @entity293 . Using a cutoff of 1 ng/ml for PCT and 20 mg/l for @entity1851 , sensitivity and specificity in distinguishing between @entity293 with and without @entity8 were 92.3 and 61.9%, respectively, for PCT and 92.3 and 34.4% for @entity1851 . Positive and negative predictive values were 32 and 97.5%, respectively, for PCT and 23 and 95%, respectively, for @entity1851 . CONCLUSIONS: A low PCT value at admission indicates a low risk of long term @entity8 . Increased PCT values at admission correlate with the presence of scars. PCT values have proved to be more specific than @entity1851 and leukocyte count for identifying @entity1 who might develop @entity8 .

title: Elevated serum @entity1904 values correlate with XXXX in @entity1 with @entity293 .

entities_list: @entity1 :: ('9606', 'Species') :: ['children', 'patients']

entities_list: @entity29582 :: ('MESH:D019783', 'Chemical') :: ['99mTc-dimercaptosuccinic acid']

entities_list: @entity8 :: ('MESH:D007674', 'Disease') :: ['renal scars', 'renal damage', 'renal scarring']

entities_list: @entity1904 :: ('MESH:C029100', 'Chemical') :: ['Procalcitonin']

entities_list: @entity2348 :: ('MESH:D001424', 'Disease') :: ['bacterial infection']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity2885 :: ('MESH:D011704', 'Disease') :: ['acute pyelonephritis']

entities_list: @entity293 :: ('MESH:D014552', 'Disease') :: ['urinary tract infection', 'UTI', 'Urinary tract infection']

entities_list: @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']

answer: @entity8 :: (MESH:D007674,Disease) :: ['renal scarring']


abstract: PURPOSE: We sought to determine @entity1 characteristics associated with hospital admission after emergency treatment for @entity565 , and whether disposition guidelines are followed. SUBJECTS AND METHODS: We performed a prospective multicenter cohort study involving 64 emergency departments in the United States and Canada. Consecutive adult @entity1 with @entity565 exacerbations were interviewed, and their charts were reviewed using standardized protocols. Telephone follow-up at 2 weeks determined relapse. RESULTS: Of 1805 @entity1 , 363 (20%; 95% confidence interval [CI]: 18% to 22%) were hospitalized. Among @entity1 with severe exacerbations (final peak flow <50% of predicted), 122 (49%; 95% CI: 43% to 55%) were hospitalized. Admission was associated with final peak flow, female sex, nonwhite race, severity of @entity102 , and severity of exacerbation. Admission predictors were similar regardless of hospital funding, region, or size. Among @entity1 with mild or moderate exacerbations of @entity565 (peak flow >or=50% predicted), the likelihood of admission was associated significantly with the number of predefined risk factors for @entity204 from @entity565 . Of @entity1 who were discharged from the emergency department, 62 (5%; 95% CI: 4% to 6%) relapsed within 72 hours. Relapse was not associated with final peak flow (P = 0.39). CONCLUSION: Associations between @entity1 characteristics and disposition were similar across sites. Despite guidelines to the contrary, half of @entity1 with final peak flow <50% were discharged. After emergency department treatment and discharge, short-term relapse was uncommon among @entity1 with @entity565 , suggesting that strict peak flow cutoffs may be unnecessary if risk factors in @entity1 with mild or moderate exacerbations are considered.

title: A prospective multicenter study of factors associated with hospital admission among adults with acute XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity102 :: ('MESH:D002908', 'Disease') :: ['chronic illness']

answer: @entity565 :: (MESH:D001249,Disease) :: ['asthma']


abstract: INTRODUCTION: @entity2816 has recently proven to be a useful drug for treatment of refractory and relapsed multiple @entity1582 @entity1 , up to 35% of whom achieve remission. However, little is known about the potential additive or synergistic effect upon its association with other drugs with proven efficacy in MM. MATERIAL AND METHODS: The present pilot study was designed to evaluate the @entity137 and response rate of the association of @entity2816 , @entity786 and @entity619 (ThaCyDex) in 22 refractory or relapsed MM @entity1 . The protocol scheduled the administration of @entity2816 at escalating doses (200 to 800 mg/day), daily oral @entity786 (CTX) (50 mg/day) and pulsed @entity619 (40 mg/day, four days every three weeks). RESULTS: Adverse effects were moderate (grade <or=2) with only two @entity1 in whom treatment was withdrawn due to @entity16 and severe @entity2147 . Infections were recorded in six @entity1 , four requiring hospitalization for intravenous antibiotic therapy. No cases of @entity882 grade >or=2 were noted. Other side effects included grade <or=2 constipation (29%), @entity2147 (35%) or @entity1296 (12%). In addition, one case of @entity19140 paresthetica and one with a @entity1150 were noted. Two cases displayed @entity4854 and @entity121 attributed to @entity619 , which was solved upon changing to @entity229 . With a median follow-up of 12 months, 17 @entity1 were evaluable for response; 13 (77%) responded to the therapy, including nine cases (53%) with a >50% M-component reduction (two of them with a complete remission). Only two responders have already progressed, with a projected event free survival of 51% at 12 months. Seven @entity1 have died due to disease progression (n=5), @entity944 (n=1) and @entity281 (n=1). CONCLUSION: This study shows that ThaCyDex is a feasible and promising therapeutic approach for @entity1 with relapsed/refractory MM.

title: The combination of @entity2816 , XXXX and @entity619 (ThaCyDex) is feasible and can be an option for relapsed/refractory multiple @entity1582 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity121 :: ('MESH:D009135', 'Disease') :: ['myopathy']

entities_list: @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia']

entities_list: @entity944 :: ('MESH:D003645', 'Disease') :: ['sudden death']

entities_list: @entity229 :: ('MESH:D011241', 'Chemical') :: ['prednisone']

entities_list: @entity16 :: ('MESH:D009422', 'Disease') :: ['neuropathy']

entities_list: @entity2816 :: ('MESH:D013792', 'Chemical') :: ['Thalidomide', 'thalidomide']

entities_list: @entity786 :: ('MESH:D003520', 'Chemical') :: ['cyclophosphamide']

entities_list: @entity2147 :: ('MESH:D006970', 'Disease') :: ['somnolence']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity1150 :: ('MESH:D020246', 'Disease') :: ['deep venous thrombosis']

entities_list: @entity1296 :: ('MESH:D004244', 'Disease') :: ['dizziness']

entities_list: @entity4854 :: ('MESH:D006943', 'Disease') :: ['hyperglycemia']

answer: @entity786 :: (MESH:D003520,Chemical) :: ['cyclophosphamide']


abstract: BACKGROUND: Stratified @entity3558 -producing intraepithelial lesion (SMILE) is an uncommon variant of in situ @entity189 . This study aimed to identify the cytologic features of SMILE since these have not been well documented previously. METHODS: The study group comprised 34 consecutive cases of SMILE encountered at a single institution in which a corresponding Papanicolaou smear, taken up to 12 months before histologic diagnosis, was available for review. The presence of associated cervical @entity1313 including @entity3146 ( @entity3146 ), @entity15709 ( @entity15709 ), and @entity189 was recorded. The linear extent and distribution of the SMILEs was also noted. RESULTS: Most Pap smears had been reported to show possible or definite high-grade @entity3146 although 3 cases reported the presence of a high-grade glandular abnormality. No case had a prospective cytologic diagnosis of SMILE. Histology revealed concurrent @entity3146 and/or @entity15709 in all cases, and 1 specimen (3%) showed invasive @entity420 . Following smear review, 23 of the 31 cases that included endocervical material showed recurrent cytologic features that appeared consistent with SMILE. These included three dimensional cell clusters with nuclear stratification and crowding, mild nuclear atypia, cytoplasmic vacuoles, mitotic figures, and apoptosis. CONCLUSION: SMILE is almost always associated with additional HPV-related @entity1313 although only one @entity1 (3%) had @entity189 , a lower rate than recorded in other studies. Consistent cytologic features associated with SMILE were identified but these were relatively subtle. However, increased awareness of these features may permit prospective diagnosis and this could influence @entity1 management. Diagn. Cytopathol. 2015.    2015 Wiley Periodicals, Inc.

title: Cytologic findings in stratified XXXX -producing intraepithelial lesion of the cervix: A report of 34 cases.

entities_list: @entity1313 :: ('MESH:D001932', 'Disease') :: ['neoplastic lesions']

entities_list: @entity189 :: ('MESH:D002277', 'Disease') :: ['carcinoma of the cervix', 'invasive carcinoma']

entities_list: @entity15709 :: ('MESH:D065311', 'Disease') :: ['AIS', 'adenocarcinoma in situ']

entities_list: @entity420 :: ('MESH:D000230', 'Disease') :: ['adenocarcinoma']

entities_list: @entity3146 :: ('MESH:D018290', 'Disease') :: ['cervical intraepithelial neoplasia', 'CIN']

answer: @entity3558 :: (100508689,Gene) :: ['mucin']


abstract: BACKGROUND AND PURPOSE: In @entity1 with @entity2500 , therapeutic decisions are influenced by the location of the occlusion. This study aimed to analyze clinical outcomes in @entity1 with @entity2500 treated with systemic @entity5275 ( @entity5275 ) using recombinant tissue plasminogen activator, according to the location of the occlusion. METHODS: Of 621 @entity1 screened, 136 with @entity64 and MCA occlusion confirmed by CT angiography were retrospectively included in this study. The distance from the carotid T to the @entity715 (DT) on coronal maximum intensity projection images and the @entity715 length were measured. The correlation between DT and the modified Rankin Scale score at 90 days was analyzed. RESULTS: DT was an independent predictor of clinical outcome in @entity64 @entity1 treated with @entity5275 . A long DT was significantly correlated with a good clinical outcome (modified Rankin Scale score at 90 days  <=2). A poor clinical outcome was exponentially more likely than a good outcome when the DT was <16 mm (P<0.001). The @entity715 length was not correlated with the modified Rankin Scale score at 90 days. A long @entity715 (>8 mm) occurred significantly more often in the proximal MCA than the distal MCA (P<0.001). CONCLUSION: DT is an independent predictor of clinical outcome in @entity1 with @entity2500 treated with @entity5275 . In @entity64 with MCA occlusion confirmed by CT angiography and DT <16 mm, the likelihood of a good clinical outcome after treatment with @entity5275 was exponentially <50%. This might warrant the evaluation of other therapy forms than @entity5275 in @entity1 with @entity2500 .

title: Distance to @entity715 in Acute XXXX : A Predictor of Outcome After Intravenous Thrombolysis for Acute Ischemic Stroke.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke', 'acute stroke']

entities_list: @entity5275 :: ('MESH:D015819', 'Disease') :: ['IVT', 'intravenous thrombolysis']

entities_list: @entity2500 :: ('MESH:D020244', 'Disease') :: ['acute MCA occlusion', 'proximal MCA occlusion', 'acute ischemic MCA stroke', 'acute middle cerebral artery (MCA) stroke']

entities_list: @entity715 :: ('MESH:D013927', 'Disease') :: ['thrombus']

answer: @entity2500 :: (MESH:D020244,Disease) :: ['Middle Cerebral Artery Occlusion']


abstract: OBJECTIVE: To evaluate the effects of age, gender, tibial anterior laxity and time from surgery to follow-up on @entity1844 status after anterior cruciate ligament reconstruction by second-look arthroscopy. METHODS: A total of 102 @entity1 undergoing arthroscopic anterior cruciate ligament reconstruction received second-look arthroscopy at least one year after operation. There were 71 males and 31 females with an average age of 27.1 (16-41) years. The average time from primary operation to second-look arthroscopy was 23 (12-51) months. Arthroscopic evaluations of patella and trochlea cartilage status for all @entity1 were performed at initial anterior cruciate ligament reconstruction and second-look arthroscopy. The effects of age, gender, tibial anterior laxity and time from surgery to follow-up on @entity1844 status were retrospectively examined. RESULTS: Patellofemoral articular cartilage degeneration continued to aggravate after anterior cruciate ligament reconstruction. There was no significant gender difference in patella and trochlear cartilage status. The patellar cartilage of @entity1 under 30 years was worse than that of @entity1 aged 30 years and above. Even though there was no significant difference. However, no significant inter-group difference existed in trochlear cartilage damage. With regard to KT-2000 side-to-side differences (0-3 mm vs >3 mm), no significant difference existed in patella and trochlear cartilage status. No significant difference was also found in the status of patella and trochlear cartilage between @entity1 with body mass index under 24 kg/m(2) and @entity1 24 kg/m(2) and higher. The patellar cartilage of @entity1 within 24 months after operation was significantly worse than that of @entity1 24 months and longer. However it did not apply to trochlear cartilage. CONCLUSION: The degeneration of @entity1844 worsens after anterior cruciate ligament reconstruction. And significantly more severe lesions are found in patellar cartilage of @entity1 within 24 months after operation.

title: [Predisposing factors of XXXX injury after anterior cruciate ligament reconstruction].

entities_list: @entity1844 :: ('MESH:D002357', 'Disease') :: ['patellofemoral articular cartilage']

answer: @entity1844 :: (MESH:D002357,Disease) :: ['patellofemoral articular cartilage']


abstract: In 22 families with the "pure" form of @entity9718 inheritance was autosomal dominant in 19 and autosomal recessive in three. Examination of intrafamilial correlation of age of onset in the dominant cases suggested that the disorder is genetically heterogeneous. Two forms of dominant @entity9718 were identified: one with an age of onset mostly below 35 years (type I), and the other onset usually over 35 years (type II). In the type I cases, delay in walking was not infrequent and @entity508 of the lower limbs was more marked than weakness. The disorder was very slowly progressive and was extremely variable in terms of severity. Sixteen per cent of the @entity1 aged over 20 years were asymptomatic but clinically affected. In the type II group muscle weakness, @entity1494 and sensory loss were more marked. This form of the disease evolved more rapidly. In the three families demonstrating autosomal recessive inheritance the clinical features were very similar to those of the dominant cases. Biological fitness of @entity1 from both the dominant groups was not impaired and no definite evidence of new mutation was observed. A cumulative frequency curve of age of onset in the type I group was constructed with suggested that an asymptomatic @entity1 of an affected parent has a 20% chance of developing the disease at the age of 25 years; the risk is probably even less if the @entity1 is clinically normal.

title: XXXX : a clinical and genetic study of 22 families.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'child']

entities_list: @entity9718 :: ('MESH:D015419', 'Disease') :: ['hereditary spastic paraplegia']

entities_list: @entity508 :: ('MESH:D009128', 'Disease') :: ['spasticity']

entities_list: @entity1494 :: ('MESH:D001745', 'Disease') :: ['urinary symptoms']

answer: @entity9718 :: (MESH:D015419,Disease) :: ['Hereditary "pure" spastic paraplegia']


abstract: Only a few angiographic studies have correlated the presence and severity of @entity453 with @entity731 in other arteries. The presence of disease in more than 1 area clearly has important implications on management. One hundred and seventy eight @entity1 had angiographic evaluation of their peripheral arteries and abdominal aorta after routine diagnostic coronary angiography. The extent and severity of @entity455 was correlated with those of @entity453 . Of the 178 @entity1 , 73.6% were @entity1 (mean age +/- sd was 52.93 +/- 10.12 years). @entity1007 (59%), systemic @entity101 (56.7%) and @entity6 (50.6%) were the major risk factors. @entity453 was present in 48.9%, and 13.5% had normal coronaries. A new @entity731 score, which reflects the presence and severity of @entity731 elsewhere, was seen to correlate significantly with the extent of @entity453 . Of particular interest was the involvement of the first part of the vertebral artery in 41.6% of @entity1 . The combined involvement of the abdominal aorta, renal artery, and iliac artery segments (together referred to as the lower body segment) was seen almost exclusively in those with 2- or 3-vessel @entity453 . Also there was a direct correlation between the extent of @entity453 and the score in the lower body segment as opposed to the upper body segment (subclavian, vertebral, and internal mammary arteries). The presence of @entity731 correlated with the severity of @entity453 , particularly in respect to disease in the lower body segment. Thus early detection of such disease in the iliac or femoral arteries has a potential for early diagnosis of significant @entity453 .

title: Extent and severity of @entity731 in XXXX undergoing coronary angiography--the Kuwait Vascular Study.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'men']

entities_list: @entity455 :: ('MESH:D014652', 'Disease') :: ['vascular disease']

entities_list: @entity1007 :: ('MESH:D006937', 'Disease') :: ['Hypercholesterolemia']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity731 :: ('MESH:D050197', 'Disease') :: ['atherosclerosis', 'atherosclerotic vascular disease']

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetes mellitus']

entities_list: @entity453 :: ('MESH:D003324', 'Disease') :: ['coronary artery disease', 'Triple-vessel coronary artery disease']

answer: @entity1 :: (9606,Species) :: ['patients']


abstract: UNASSIGNED: @entity3969 ( @entity3969 ) are large heterogeneous @entity5 , which typically consist of a mixture of histological cell types, together with regions of chemotherapy-induced regressive change and @entity39 . The predominant cell type in a @entity7097 is assessed histologically following nephrectomy, and used to assess the @entity5 subtype and potential risk. The purpose of this study was to develop a mathematical model to identify subregions within @entity3969 with distinct cellular environments in vivo, determined using apparent diffusion coefficient (ADC) values from diffusion-weighted imaging (DWI). We recorded the @entity7097 subtype from the histopathology of 32 @entity5 resected in @entity1 who received DWI prior to surgery after pre-operative chemotherapy had been administered. In 23 of these @entity5 , DWI data were also available prior to chemotherapy. Histograms of ADC values were analysed using a multi-Gaussian model fitting procedure, which identified 'subpopulations' with distinct cellular environments within the @entity5 volume. The mean and lower quartile ADC values of the predominant viable tissue subpopulation (ADC1MEAN , ADC1LQ ), together with the same parameters from the entire @entity5 volume (ADC0MEAN , ADC0LQ ), were tested as predictors of @entity7097 subtype. ADC1LQ from the multi-Gaussian model was the most effective parameter for the stratification of @entity7097 subtype, with significantly lower values observed in high-risk blastemal-type @entity3969 compared with intermediate-risk stromal, regressive and mixed-type @entity3969 (p   <   0.05). No significant difference in ADC1LQ was found between blastemal-type and intermediate-risk epithelial-type @entity3969 . The predominant viable tissue subpopulation in every stromal-type @entity7097 underwent a positive shift in ADC1MEAN after chemotherapy. Our results suggest that our multi-Gaussian model is a useful tool for differentiating distinct cellular regions within @entity3969 , which helps to identify the predominant histological cell type in the @entity5 in vivo. This shows potential for improving the risk-based stratification of @entity1 at an early stage, and for guiding biopsies to target the most malignant part of the @entity5 . Copyright    2015 John Wiley _ Sons, Ltd.

title: A multi-Gaussian model for apparent diffusion coefficient histogram analysis of XXXX subtype and response to chemotherapy.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity39 :: ('MESH:D009336', 'Disease') :: ['necrosis']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumours', 'tumour']

entities_list: @entity3969 :: ('MESH:D009396', 'Disease') :: ["Wilms' tumours", 'WTs']

answer: @entity3969 :: (MESH:D009396,Disease) :: ['Wilms' tumour']


abstract: BACKGROUND: In animal models, brief periods of @entity63 performed just at the time of reperfusion can reduce @entity1188 size, a phenomenon called postconditioning. In this prospective, randomized, controlled, multicenter study, we investigated whether postconditioning may protect the @entity1 heart during coronary angioplasty for @entity583 . METHODS AND RESULTS: Thirty @entity1 , submitted to coronary angioplasty for ongoing @entity583 , contributed to the study. @entity1 were randomly assigned to either a control or a postconditioning group. After reperfusion by direct stenting, control subjects underwent no further intervention, whereas postconditioning was performed within 1 minute of reflow by 4 episodes of 1-minute inflation and 1-minute deflation of the angioplasty balloon. @entity1188 size was assessed by measuring total @entity908 kinase release over 72 hours. Area at risk and collateral blood flow were estimated on left ventricular and coronary angiograms. No adverse events occurred in the postconditioning group. Determinants of @entity1188 size, including @entity63 time, size of the area at risk, and collateral flow, were comparable between the 2 groups. Area under the curve of @entity908 kinase release was significantly reduced in the postconditioning compared with the control group, averaging 208 984+/-26 576 compared with 326,095+/-48,779 (arbitrary units) in control subjects, ie, a 36% reduction in @entity1188 size. Blush grade, a marker of myocardial reperfusion, was significantly increased in postconditioned compared with control subjects: 2.44+/-0.17 versus 1.95+/-0.27, respectively (P<0.05). CONCLUSIONS: This study suggests that postconditioning by coronary angioplasty protects the @entity1 heart during @entity583 .

title: Postconditioning the XXXX heart.

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'human', 'patients']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity908 :: ('MESH:D003401', 'Chemical') :: ['creatine']

entities_list: @entity1188 :: ('MESH:D007238', 'Disease') :: ['Infarct', 'infarct']

entities_list: @entity583 :: ('MESH:D009203', 'Disease') :: ['acute myocardial infarction']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND: @entity842 (NO) is greatly increased in the colon of @entity1 with @entity29 of different aetiology, including @entity4143 . In @entity1 , NO can be generated from NO synthases as well as from non-enzymatic sources. The source of the NO found in luminal intestinal gas has not been exactly pinpointed. We investigated the effect of the NO synthase inhibitor @entity7293 on intestinal concentrations of NO in @entity1 with clinically active @entity4143 . In addition, we measured NO levels from the respiratory tract. METHODS: Ten @entity1 with active @entity4143 were studied. NO levels were measured from the respiratory tract and in the rectum before and after i.v. administration of @entity7293 (7.5 mg/kg) using a chemiluminescence method. RESULTS: Airway NO release decreased markedly, and mean arterial blood pressure increased in all @entity1 following @entity7293 treatment. Basal rectal NO levels were high (median > 10000 ppb) and decreased markedly in 5 @entity1 after @entity7293 . In contrast, NO levels remained completely unchanged or even increased in the other 5 @entity1 . CONCLUSION: Rectal levels of NO are greatly increased in @entity1 with symptomatic @entity4143 . Intravenous administration of an NO synthase inhibitor reduced rectal NO only in half of the @entity1 despite clear evidence of effective systemic NO synthase inhibition. This could indicate alternative @entity3623 -independent sources of intestinal NO in this disease.

title: Effect of intravenous @entity7293 on XXXX production in @entity4143 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'man']

entities_list: @entity29 :: ('MESH:D015212', 'Disease') :: ['inflammatory bowel disease']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['Nitric oxide']

entities_list: @entity4143 :: ('MESH:D046729', 'Disease') :: ['collagenous colitis']

answer: @entity842 :: (MESH:D009569,Chemical) :: ['nitric oxide']


abstract: BACKGROUND: Aberrant histone acetylation has been observed in @entity105 and cellular transformation associated with @entity3494 exposure; however, the molecular mechanisms and cellular outcomes of such changes are poorly understood. OBJECTIVE: We investigated the impact of tolerated and toxic @entity4447 ( @entity9188 ) exposure in @entity1 embryonic kidney (HEK293T) and urothelial (UROtsa) cells to characterize the alterations in histone acetylation and gene expression as well as the implications for cellular transformation. METHODS: Tolerated and toxic exposures of @entity9188 were identified by measurement of cell death, mitochondrial function, cellular proliferation, and anchorage-independent growth. Histone extraction, the MNase sensitivity assay, and immunoblotting were used to assess global histone acetylation levels, and gene promoter-specific interactions were measured by chromatin immunoprecipitation followed by reverse-transcriptase polymerase chain reaction. RESULTS: Tolerated and toxic dosages, respectively, were defined as 0.5  M and 2.5  M @entity9188 in HEK293T cells and 1  M and 5  M @entity9188 in UROtsa cells. Global hypoacetylation of H3K9 at 72 hr was observed in UROtsa cells following tolerated and toxic exposure. In both cell lines, tolerated exposure alone led to H3K9 hyperacetylation and @entity16262 binding at the @entity1639 promoter, which remained elevated after 72 hr, contrary to global H3K9 hypoacetylation. Thus, promoter-specific H3K9 acetylation is a better predictor of cellular transformation than are global histone acetylation patterns. Tolerated exposure resulted in an increased expression of the proto-oncogenes @entity1639 and @entity1178 in both cell lines at 72 hr. CONCLUSION: Global H3K9 hypoacetylation and promoter-specific hyperacetylation facilitate @entity16262 -mediated @entity1639 induction in @entity9188 -induced cellular transformation. CITATION: Rahman S, Housein Z, Dabrowska A, May  n MD, Boobis AR, Hajji N. 2015. @entity16262 -mediated @entity1639 induction in @entity4447 -induced cellular transformation: effects of global H3K9 hypoacetylation and promoter-specific hyperacetylation in vitro. Environ Health Perspect 123:484-492;   http://dx.doi.org/10.1289/ehp.1408302.

title: @entity16262 -Mediated @entity1639 Induction in XXXX -Induced Cellular Transformation: Effects of Global H3K9 Hypoacetylation and Promoter-Specific Hyperacetylation in Vitro.

entities_list: @entity4447 :: ('MESH:C006632', 'Chemical') :: ['arsenic trioxide']

entities_list: @entity105 :: ('MESH:D063646', 'Disease') :: ['carcinogenesis']

answer: @entity4447 :: (MESH:C006632,Chemical) :: ['Arsenic Trioxide']


abstract: The aim of this study was to examine the activities of hASCs ( @entity1 Adipose tissue Derived Stem Cells) on @entity393 ( @entity393 ) and how @entity1 stem cells regenerated @entity19 cochlea cells. We have restored hearing in 19 years old white female with @entity393 with autologous adipose tissue derived stem cells and we wish to understand the mechanism of restoration of hearing in animal model. BALB/c @entity19 underwent to develop @entity393 ; @entity19 with @entity393 were given hASCs intraperitoneally once a week for 6 consecutive weeks. ABR were examined over time. The helper type 1 autoreactive responses and T-reg cells were examined. H_E staining or immunostaining with @entity1412 conjugated anti-HLA-ABC antibody were conducted. The organ of Corti, stria vascularis, spira ligament and @entity4494 in stem cell group are normal. In control group, without receiving stem cells, the organ of Corti is replaced by a single layer of cells, atrophy of stria vascularis. Systemic infusion of hASCs significantly improved hearing function and protected hair cells in established @entity393 . The hASCs decreased the proliferation of antigen specific @entity1198 /Th17 cells and induced the production of anti-inflammatory cytokine @entity688 in splenocytes. They also induced the generation of antigen specific @entity404 (+)CD25(+)Foxp3(+)T-reg cells. The experiment showed the restoration is due to the paracrine activities of @entity1 stem cells, since there are newly regenerated @entity19 @entity4494 cells, not @entity1 mesenchymal stem cells derived tissue given by intraperitoneally. This article is part of a Special Issue entitled <IEB Kyoto>.

title: The paracrine effect of mesenchymal XXXX stem cells restored hearing in b-tubulin induced autoimmune sensorineural hearing loss.

entities_list: @entity4494 :: ('MESH:D045888', 'Disease') :: ['spiral ganglion']

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['experimental autoimmune hearing loss', 'autoimmune hearing loss', 'EAHL']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: UNASSIGNED: This study aims to investigate the depth distribution of the @entity1507 Reduction Potential (NRP) on a natural and a re-established wetland. The obtained NRP provides a valuable data of the driving factors affecting denitrification, the Dissimilatory @entity1507 Reduction to @entity16764 (DNRA) process and the performance of a re-established wetland. Intact soil cores were collected and divided in slices for the determination of Organic Matter (OM) through @entity393 ( @entity393 ) as well as Dissolved Organic @entity505 (DOC) and NRP spiking @entity1507 in batch tests. The @entity1507 Reduction (NR) was fitted as a pseudo-first order rate constant (k) from where NRPs were obtained. NR took place in a narrow superficial zone showing a dropping natural logarithmic trend along depth. The main driving factor of denitrification, besides depth, was OM. Although, DOC and @entity393 could not express by themselves and absolute correlation with NRP, high amounts of DOC ensured enough quantity and quality of labile OM for NR. Besides, high concentration of @entity393 but a scarce abundance of DOC failed to drive NR. DNRA was only important in superficial samples with high contents of OM. Lastly, the high NRP of the re-established wetland confirms that wetlands can be restored satisfactorily.

title: Subsurface XXXX reduction under wetlands takes place in narrow superficial zones.

entities_list: @entity393 :: ('MESH:D034381', 'Disease') :: ['LOI', 'Loss of Ignition']

entities_list: @entity1507 :: ('CHEBI:48107', 'Chemical') :: ['nitrate', 'Nitrate']

answer: @entity1507 :: (CHEBI:48107,Chemical) :: ['nitrate']


abstract: AIMS: To determine the systemic dose-response relationships with oral @entity617 and inhaled @entity5023 administered in a putative 11:1 mg equivalent basis, in terms of effects on adrenal, bone and haematological markers. METHODS: Twelve @entity748 @entity1 mean (s.e.) age, 28.8 [3.3] years, FEV1 94.7 [3.6]% predicted, FEF(25-75) 65.5 [6.1]% predicted were studied in a double-blind, double dummy randomised crossover design comparing placebo, inhaled @entity5023 via volumatic spacer given twice a day (ex actuator dose 0.44 mg day-1, 0.88 mg day-1, 1.76 mg day-1 ) and oral @entity617 given once daily (5 mg day-1, 10 mg day-1, 20 mg day-1 ). All treatments were for 4 days at each dose level with a 7-day washout at crossover. Measurements were made at 08.00 h after the last dose of each dose level for plasma @entity701 , serum osteocalcin and blood eosinophil count. RESULTS: There were significant dose-related effects for suppression of all three endpoints with both @entity617 and @entity5023 . Parallel slope analysis revealed a calculated dose ratio for relative potency of 8. 5:1 mg (95% CI 5.7-11.2) comparing Pred with FP for morning @entity701 . The magnitude of suppression with FP was less for osteocalcin and eosinophils than for @entity701 . CONCLUSIONS: Systemic tissues exhibit different dose-response relationships for the effects of inhaled and oral corticosteroids with suppression of @entity701 being greater than osteocalcin or eosinophils. For @entity701 suppression we observed an 8.5:1 mg relative potency ratio comparing @entity617 with @entity5023 . @entity1 taking high dose inhaled @entity5023 should therefore be screened for evidence of impaired adrenal reserve.

title: Short-term dose-response relationships for the relative systemic effects of oral @entity617 and inhaled XXXX in @entity748 adults.

entities_list: @entity748 :: ('MESH:D013224', 'Disease') :: ['asthmatic']

entities_list: @entity1 :: ('9606', 'Species') :: ['Patients', 'patients']

entities_list: @entity701 :: ('MESH:D006854', 'Chemical') :: ['cortisol']

entities_list: @entity5023 :: ('MESH:C065382', 'Chemical') :: ['fluticasone propionate']

entities_list: @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone']

answer: @entity5023 :: (MESH:C065382,Chemical) :: ['fluticasone']


abstract: @entity27889 ( @entity27889 ) is a chronic, uncommon, sub-epidermal blistering disease involving the skin and mucous membranes that heals with @entity2318 formation and @entity46117 . Collagens, matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) are important components that play an essential role(s) in matrix remodeling during @entity2318 formation. However, the possible involvement of these components in @entity27889 -induced scarring is not yet known. In the present study, we examined the expression profile of collagens, collagen-binding @entity17381 ( @entity17381 ), MMPs and their inhibitory enzymes, TIMPs, in matrix remodeling during conjunctival scarring. The involvement of @entity2533 , a fibrogenic factor, was also studied. Compared to the controls, an increased expression of type I collagen, type III collagen and @entity17381 was detected in conjunctival biopsy sections of @entity1 with @entity27889 using immunohistochemistry. Similar increase in the expression of type I collagen, type III collagen and @entity17381 was noted in conjunctival fibroblasts obtained from the @entity1 with @entity27889 . Up-regulation in the expression of @entity3334 and @entity1551 was also noted in conjunctival fibroblasts isolated from the @entity1 with @entity27889 , while no significant changes in the expression of @entity1549 , @entity5952 , @entity1495 and @entity1550 were seen. As for TIMPs, conjunctival fibroblasts isolated from the @entity1 with @entity27889 , grown in vitro, exhibited increased expression of @entity2843 , @entity1552 and @entity8111 , when compared with fibroblasts grown from control conjunctival tissues, although the expression level varies with different molecules of the same family. Additionally, compared to the control conjunctival fibroblasts, an increased expression of @entity2533 was detected in fibroblasts isolated from the conjunctival tissues of @entity1 with @entity27889 . This study suggests that there is up-regulation in the production of collagens (type I and III), collagen-binding protein ( @entity17381 ), matrix degrading collagenases ( @entity64212 ), and their inhibitory enzymes ( @entity34189 ) during the process of conjunctival matrix remodeling in the @entity1 with @entity27889 . The presented data is preliminary and could serve as a basis for further studies to enhance our understanding about the molecular mechanisms of conjunctival scarring in @entity1 with @entity27889 .

title: Expression profiles of collagens, @entity17381 , XXXX , MMPs and TIMPs in epidermolysis bullosa acquisita.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity27889 :: ('MESH:D016107', 'Disease') :: ['EBA', 'Epidermolysis bullosa acquisita']

answer: @entity2533 :: (7040,Gene) :: ['TGF-beta1']


abstract: BACKGROUND: @entity528 in @entity6391 ( @entity6391 ) runs an inevitable, gradually progressive course. A wide variety of growth factors of different origins have been shown to slow the rate of degeneration in some rodent models of @entity6391 . Recently, lens-derived neurotrophic factors have been shown to rescue degenerating @entity4494 cells in crush models of the optic nerve. Our objective was to evaluate the potential rescue effect of lensectomy and vitrectomy (L_V) on @entity528 in a large-animal model, the @entity26280 @entity38334 transgenic @entity1707 . METHODS: We operated on one eye of each of 49 3-week-old @entity1707 --15 vitrectomies and 34 L_V, 6 of which received @entity230 . Retinal paraffin sections were prepared for all eyes, in addition to immunohistochemistry in four eyes, 8 weeks after L_V. RESULTS: At eight weeks after L_V, operated eyes showed significantly more nuclei in the outer nuclear layer (ONL) than the unoperated fellow eyes. The better preservation of the ONL persisted but was less prominent by 20 weeks after surgery. @entity134 treatment did not markedly reduce the better preservation of the ONL seen at 8, 10, and 12 weeks after surgery. The significant difference in cell count between operated and unoperated eyes in the L_V group at 8 weeks was due to the difference in the number of rods, not the cones. CONCLUSION: Lensectomy and vitrectomy delay @entity528 in @entity26280 @entity38334 transgenic @entity1707 . Lens-related rescue effect is a probable reason for the @entity528 .

title: Lensectomy and vitrectomy decrease the rate of photoreceptor loss in @entity26280 @entity38334 transgenic XXXX .

entities_list: @entity6391 :: ('MESH:D012174', 'Disease') :: ['retinitis pigmentosa', 'RP']

entities_list: @entity134 :: ('CHEBI:35341', 'Chemical') :: ['Steroid']

entities_list: @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids']

entities_list: @entity528 :: ('MESH:D009410', 'Disease') :: ['photoreceptor degeneration', 'Photoreceptor degeneration', 'delayed degeneration']

answer: @entity1707 :: (9823,Species) :: ['pigs']


abstract: OBJECTIVES: We evaluated the results of treatment of adult @entity3330 treated by intramedullary nails. METHODS: Sixty-two @entity1 (15 females, 48 males; mean age 29 years; range 16 to 62 years) with 64 @entity3330 were treated by intramedullary nailing. Eighty-three percent of the @entity174 was closed and 17% was open. According to the Winquist (W) classification, there were 16 (25%) W0, 22 (34%) W1, nine (14%) W2, nine (14%) W3, and eight (13%) W4 @entity174 . The mean duration between @entity130 and surgery was 18 days (range 4 to 130 days), and the mean hospital stay was 25 days (range 11 to 142 days). Open and closed techniques were employed in 62 (97%) and two (3%) @entity174 , respectively. Nine @entity174 were unlocked; dynamic and static locking were performed in 39 and 16 @entity174 , respectively. In the open technique, secondary procedures involved grafting in 14 cases, cerclage in eight cases, grafting and cerclage in 10 cases, and grafting and screw fixation in one case. The results were assessed according to the criteria by Thoresen et al. The mean follow-up was 28 months (range 7 to 62 months). RESULTS: Fifty-one @entity1 (80%) had satisfactory, 13 @entity1 (20%) had poor outcome. All proximal locking screws (n=20) were successfully inserted, whereas 23 (24%) of 95 distal screws missed the nail holes. Complications included superficial @entity281 (n=3), @entity4034 (n=4), @entity2585 (n=1), irritation of the skin by the distal screws (n=4), @entity2736 (n=6), shortening more than 1 cm (n=8), @entity717 greater than 10 degrees (n=2), migration of the nail through the knee joint (n=2), drill breakage while preparing the distal holes (n=2), knee range of motion below 100 degrees (n=6), and delayed union (n=2). CONCLUSION: Intramedullary nailing should be the primary indication for stable and unstable @entity3330 .

title: [Intramedullary nailing of adult XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity174 :: ('MESH:D050723', 'Disease') :: ['fractures']

entities_list: @entity4034 :: ('MESH:D010019', 'Disease') :: ['osteomyelitis']

entities_list: @entity281 :: ('MESH:D007239', 'Disease') :: ['infection']

entities_list: @entity2585 :: ('MESH:D002062', 'Disease') :: ['trochanteric bursitis']

entities_list: @entity2736 :: ('MESH:D009999', 'Disease') :: ['heterotopic ossification']

entities_list: @entity717 :: ('MESH:D009069', 'Disease') :: ['rotational malalignment']

entities_list: @entity3330 :: ('MESH:D005264', 'Disease') :: ['femoral fractures']

answer: @entity3330 :: (MESH:D005264,Disease) :: ['femoral fractures']


abstract: UNASSIGNED: Epithelial to mesenchymal transition (EMT) is a developmental process which is aberrantly activated during @entity5 invasion and @entity3 . Elevated expression of EMT-inducers like @entity18075 enables @entity5 cells to detach from the primary @entity5 and invade into the surrounding tissue. The main antagonist of @entity18075 in controlling EMT is the microRNA-200 family that is reciprocally linked to @entity18075 in a double negative feedback loop. Here, we further elucidate how the @entity18075 /miR-200 feedback loop controls invasion of @entity5 cells. The process of EMT is attended by major changes in the actin cytoskeleton. Via in silico screening of genes encoding for actin interacting proteins, we identified two novel targets of @entity18076 - @entity16745 and @entity19077 ( @entity19077 ). Co-expression of both genes with @entity18075 was observed in several @entity5 cell lines as well as in @entity0 @entity1 and correlated with low @entity18076 levels. Depletion of @entity16745 or @entity19077 in @entity0 cells reduced their invasive potential and their ability to form invadopodia. Whereas @entity16745 is known to be a major component, we could identify @entity19077 as a novel player in invadopodia formation. In summary, @entity16745 and @entity19077 represent two mediators of invasive behavior of @entity5 cells that are regulated by the @entity18075 /miR-200 feedback loop.

title: The @entity18075 / XXXX feedback loop regulates invasion via actin interacting proteins @entity19077 and @entity16745 .

entities_list: @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancer']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor', 'cancer']

entities_list: @entity3 :: ('MESH:D009362', 'Disease') :: ['metastasis']

answer: @entity18076 :: (406985,Gene) :: ['miR-200c']


abstract: BACKGROUND: The differential clinical and epidemiological characteristics of @entity4806 @entity1 (< 14 years) with @entity1902 caused by rotavirus or adenovirus were studied. MATERIAL AND @entity1 : A retrospective study was performed in @entity1 with @entity1800 diagnosed from January 1990 to December 1992. The detection of viral particles was carried out by the agglutination system with latex particles sensitized with antibodies versus rotavirus and adenovirus. Clinical and epidemiological characteristics of the @entity1 were collected reviewing the medical records and emergency charts. RESULTS: Two hundred eighty-nine @entity1 corresponding to 240 cases of @entity281 by rotavirus (83.1%) and 48 (16.9%) by adenovirus, were analyzed. @entity294 by rotavirus predominated in the winter months (59.7% of the cases from December to March). Nonetheless, those caused by adenovirus were seen throughout the year with a stable incidence being observed. Statistically significant differences were seen in both groups (p < 0.001) with @entity6425 having a greater tendency to admission and greater incidence of @entity391 , fever (> 39 degrees C) and underlying disease. The presence of @entity491 was different in the adenovirus group as were the greater length of duration of @entity294 prior to attending the Emergency Department (5.2 days) and the total length of stay (11.2 days). No other associated enteropathogenic organisms were detected in 86.3% of the infections by rotavirus and in the 89.8% of those caused by adenovirus. In regard to age group distribution prevalence of @entity294 by rotavirus was observed during the first 3 months of life (76.6%) while adenovirus group it went up to 24 months of age with similar percentages. CONCLUSIONS: @entity294 by rotavirus is mainly presented in the winter, with @entity391 and its shorter in length and the symptoms less prolonged than @entity294 caused by adenovirus. Rotavirus @entity294 generally affect @entity1 admitted with some underlying disease. Nonetheless, microbiologic diagnosis is required to establish the definitive etiology of both clinical processes.

title: [Differential clinical characteristics among XXXX @entity1 with @entity1902 caused by rotavirus and adenovirus].

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PATIENTS']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea', 'Diarrhea']

entities_list: @entity4806 :: ('MESH:D063766', 'Disease') :: ['pediatric']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity1902 :: ('MESH:D005759', 'Disease') :: ['gastroenteritis']

entities_list: @entity1800 :: ('MESH:D014777', 'Disease') :: ['viral gastroenteritis']

entities_list: @entity6425 :: ('MESH:D012400', 'Disease') :: ['rotavirus infection']

entities_list: @entity491 :: ('MESH:D007964', 'Disease') :: ['leukocytosis']

answer: @entity4806 :: (MESH:D063766,Disease) :: ['pediatric']


abstract: A subset of @entity1 peripheral blood mononuclear cells (PB-MNCs) differentiate into endothelial progenitor cells (EPCs) that participate in postnatal neovascularization. Although tissue @entity63 can mobilize EPCs from bone marrow, the effects of @entity519 on differentiation and angiogenic function of EPCs are little known. We examined whether @entity519 conditioning would modulate differentiation and function of @entity1 PB-MNC-derived EPCs. A subset of PB-MNCs gave rise to EPC-like @entity10273 ( @entity10273 ) cells under either normoxic or @entity519 conditions. However, @entity519 much enhanced the differentiation of @entity10273 cells from PB-MNCs compared with normoxia. @entity10273 cells released @entity7 ( @entity7 ) protein and expressed @entity2279 and @entity319 / @entity319 , endothelial lineage markers, on their surface, which were also enhanced by @entity519 . Both a neutralizing anti- @entity7 mAb and a KDR-specific receptor @entity669 kinase inhibitor, @entity17994 , suppressed PB-MNC differentiation into EPC-like @entity10273 cells in a dose-dependent manner. Migration of @entity10273 cells in response to @entity7 as examined by a modified Boyden chamber apparatus was also enhanced by @entity519 . Finally, in vivo neovascularization efficacy was significantly enhanced by in vitro @entity519 conditioning of @entity10273 cells when cells were transplanted into the ischemic hindlimb of immunodeficient nude @entity35 . In conclusion, @entity519 directly stimulated differentiation of EPC-like @entity10273 cells from @entity1 PB-MNC culture. Moreover, @entity519 preconditioning of @entity10273 cells before in vivo transplantation is a useful means to enhance therapeutic vasculogenesis.

title: @entity519 preconditioning augments efficacy of XXXX endothelial progenitor cells for therapeutic neovascularization.

entities_list: @entity7 :: ('7422', 'Gene') :: ['vascular endothelial growth factor', 'VEGF']

entities_list: @entity63 :: ('MESH:D007511', 'Disease') :: ['ischemia']

entities_list: @entity319 :: ('3791', 'Gene') :: ['VEGFR-2', 'kinase insert domain receptor']

entities_list: @entity519 :: ('MESH:D000860', 'Disease') :: ['hypoxic', 'hypoxia']

entities_list: @entity669 :: ('CHEBI:18186', 'Chemical') :: ['tyrosine']

answer: @entity1 :: (9606,Species) :: ['human']


abstract: BACKGROUND: @entity384 ( @entity384 ) of @entity1 conduit arteries is, in part, related to shear stress-induced release of endothelium-derived @entity842 (NO). However, NO synthase inhibitors do not completely abolish this @entity384 -response. Recently, a cytochrome P450 (CYP) epoxygenase of the 2C family was linked to NO- and prostacyclin-independent relaxation of conduit arteries. We therefore evaluated the contribution of @entity5060 to @entity384 in @entity1 . METHODS AND RESULTS: @entity384 of the radial artery was determined in 12 healthy volunteers by high-resolution ultrasound and analyzed before and after intra-arterial infusion of @entity41779 , a specific @entity5060 inhibitor, @entity7293 (NO synthase inhibitor) and co-infusion of both. Endothelium-independent vasodilation was characterized after intra-arterial infusion of SNP. @entity384 was reduced after @entity41779 (11.5+/-0.87% vs. 7.4+/-0.95%, p<0.01), after @entity7293 (6.0+/-0.71%; p<0.01), and after co-infusion 3.9+/-0.73% (p<0.05 vs. @entity7293 ; p<0.01 vs. @entity41779 ). @entity41779 had no effect on endothelium-independent vasodilation. In @entity1 with @entity712 , the portion of @entity384 blocked by @entity41779 was not affected. @entity5060 was detected by immunohistochemistry in radial artery samples obtained from @entity1 undergoing coronary bypass surgery. CONCLUSIONS: @entity384 in @entity1 conductance arteries is reduced after inhibition of @entity5060 , supporting the concept that @entity5060 metabolites contribute to endothelium-mediated vasodilation of peripheral conduit arteries in vivo. In @entity1 with @entity712 , the CYP-dependent @entity384 appears to be preserved.

title: Cytochrome P450 2C9 is involved in flow-dependent vasodilation of peripheral conduit arteries in healthy subjects and in @entity1 with XXXX .

entities_list: @entity1 :: ('9606', 'Species') :: ['humans', 'human', 'patients']

entities_list: @entity712 :: ('MESH:D006333', 'Disease') :: ['chronic heart failure', 'heart failure']

entities_list: @entity384 :: ('MESH:D002311', 'Disease') :: ['Flow-mediated dilation', 'FMD']

entities_list: @entity41779 :: ('MESH:D013426', 'Chemical') :: ['sulfaphenazole', 'Sulfaphenazole']

entities_list: @entity842 :: ('MESH:D009569', 'Chemical') :: ['nitric oxide']

answer: @entity712 :: (MESH:D006333,Disease) :: ['chronic heart failure']


abstract: INTRODUCTION: The reproductive functions of @entity302 females often display alterations. This dysfunction can be due to psychological, physiological or pharmacological factors. These @entity1 have been described as having, for example, a higher incidence of @entity3205 , @entity249 , alterations affecting the @entity1640 or pituitary hormones and the peripheral sex hormones. The greater incidence of @entity3610 is subject to debate, since the prevalence varies according to the eligibility criteria used for the syndrome. DEVELOPMENT: The series that show a positive relation between @entity3610 and @entity302 tend to understand it to be a side effect of antiepileptic medication, especially @entity1092 . Two theories are considered: it has a direct action on the sex hormones or @entity3190 that is secondary to weight gain. As neurologists, in our daily practice we must show concern for the conceive. Moreover, we must determine the baseline reproductive hormonal functioning of the @entity302 female before beginning antiepileptic therapy, provide laboratory backed evidence of any @entity250 and refer them to the reproductive and sexual health of @entity302 @entity1 . To do so, we need a @entity1 record that is aimed at detecting possible problems, with special attention being given to the warning signs , such as changes in weight, variations of the menstrual cycles or mid cycle bleeding, the appearance of @entity28 , signs of virilisation, miscarriages or difficulties to endocrinologist or gynaecologist. CONCLUSIONS: Knowledge about both pathologies will enable us to modify antiepileptic therapy if the relation it has with them is confirmed, since this side effect could be reversible.

title: [ @entity3610 and XXXX ].

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'patient']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility']

entities_list: @entity3610 :: ('MESH:D011085', 'Disease') :: ['polycystic ovary syndrome']

entities_list: @entity28 :: ('MESH:D009765', 'Disease') :: ['androgynous obesity']

entities_list: @entity1640 :: ('MESH:D007027', 'Disease') :: ['hypothalamic']

entities_list: @entity1092 :: ('MESH:D014635', 'Chemical') :: ['valproic acid']

entities_list: @entity3190 :: ('MESH:D006946', 'Disease') :: ['hyperinsulinism']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epileptic', 'epilepsy']

entities_list: @entity3205 :: ('MESH:D056806', 'Disease') :: ['anovulatory cycles']

entities_list: @entity250 :: ('MESH:D012735', 'Disease') :: ['sexual function disorder']

answer: @entity1092 :: (MESH:D014635,Chemical) :: ['valproic acid']


abstract: In response to accumulation of unfolded proteins in the endoplasmic reticulum (ER), a homoeostatic response, termed the unfolded protein response (UPR), is activated in all eukaryotic cells. The UPR involves only transcriptional regulation in @entity375 , and approx. 6% of all @entity375 genes, encoding not only proteins to augment the folding capacity in the ER, but also proteins working at various stages of secretion, are induced by ER stress [Travers, Patil, Wodicka, Lockhart, Weissman and Walter (2000) Cell (Cambridge, Mass.) 101, 249-258]. In the present study, we conducted microarray analysis of HeLa cells, although our analysis covered only a small fraction of the @entity1 genome. A great majority of @entity1 ER stress-inducible genes (approx. 1% of 1800 genes examined) were classified into two groups. One group consisted of genes encoding ER-resident molecular chaperones and folding enzymes, and these genes were directly regulated by the ER-membrane-bound transcription factor @entity14920 . The ER-membrane-bound protein kinase double-stranded RNA-activated protein kinase-like ER kinase ( @entity7952 )-mediated signalling pathway appeared to be responsible for induction of the remaining genes, which are not involved in secretion, but may be important after cellular recovery from ER stress. In higher eukaryotes, the @entity7952 -mediated translational-attenuation system is known to operate in concert with the transcriptional-induction system. Thus we propose that @entity1 cells have evolved a strategy to cope with ER stress different from that of @entity375 cells.

title: Distinct roles of @entity14920 ( XXXX ) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase ( @entity7952 ) in transcription during the @entity1 unfolded protein response.

entities_list: @entity1 :: ('9606', 'Species') :: ['mammalian', 'human']

entities_list: @entity14920 :: ('22926', 'Gene') :: ['activating transcription factor (ATF) 6']

answer: @entity14920 :: (22926,Gene) :: ['ATF6']


abstract: UNASSIGNED: @entity302 is common in @entity6694 , an @entity1112 caused by mutations in the @entity8251 gene, and in @entity6694 , such as @entity8251 duplication. However, neither the longitudinal course of @entity302 nor the patterns of @entity410 onset and remission have been described in @entity6694 and related conditions. The present study summarizes the findings of the @entity6694 Natural History study. @entity1 with clinical @entity6694 and those with @entity8251 mutations without the clinical syndrome were recruited through the Rett Natural History study from 2006 to 2015. Clinical details were collected, and cumulative lifetime prevalence of @entity302 was determined using the Kaplan-Meier estimator. Risk factors for @entity302 were assessed using Cox proportional hazards models. Of 1205 @entity1 enrolled in the study, 922 had classic @entity6694 , and 778 of these were followed longitudinally for 3939 @entity1 -years. The diagnosis of atypical @entity6694 with a severe clinical phenotype was associated with higher prevalence of @entity302 than those with classic @entity6694 . While point prevalence of active @entity410 ranged from 30% to 44%, the estimated cumulative lifetime prevalence of @entity302 using Kaplan-Meier approached 90%. Specific @entity8251 mutations were not significantly associated with either @entity410 prevalence or @entity410 severity. In contrast, many clinical features were associated with @entity410 prevalence; frequency of hospitalizations, inability to walk, @entity2845 , scoliosis, @entity3685 , age of @entity410 onset, and late age of diagnosis were independently associated with higher odds of an individual having @entity302 . @entity146 was associated with lower odds. Three distinct patterns of @entity410 prevalence emerged in classic @entity6694 , including those who did not have @entity410 throughout the study, those who had frequent relapse and remission, and those who had relentless @entity410 . Although 248 of those with classic @entity6694 and a history of @entity410 were in terminal remission at last contact, only 74 (12% of those with a history of @entity302 ) were @entity410 free and off anti- @entity410 medication. When studied longitudinally, point prevalence of active @entity410 is relatively low in @entity6694 , although lifetime risk of @entity302 is higher than previously reported. While daily @entity410 are uncommon in @entity6694 , prolonged remission is less common than in other causes of childhood onset @entity302 . Complete remission off anti- @entity410 medications is possible, but future efforts should be directed at determining what factors predict when withdrawal of medications in those who are @entity410 free is propitious.

title: Longitudinal course of @entity302 in XXXX and related disorders.

entities_list: @entity1 :: ('9606', 'Species') :: ['participants', 'Participants', 'person']

entities_list: @entity410 :: ('MESH:D012640', 'Disease') :: ['seizure', 'seizures']

entities_list: @entity146 :: ('MESH:D001523', 'Disease') :: ['Aggressive behaviour']

entities_list: @entity6694 :: ('MESH:D015518', 'Disease') :: ['Rett-related disorders', 'Rett syndrome']

entities_list: @entity1112 :: ('MESH:D040181', 'Disease') :: ['X-linked dominant disorder']

entities_list: @entity2845 :: ('MESH:D018476', 'Disease') :: ['bradykinesia']

entities_list: @entity3685 :: ('MESH:D019959', 'Disease') :: ['gastrostomy feeding']

entities_list: @entity302 :: ('MESH:D004827', 'Disease') :: ['epilepsy', 'Epilepsy']

answer: @entity6694 :: (MESH:D015518,Disease) :: ['Rett syndrome']


abstract: Our objectives were to determine response rate, time to progression, overall survival and tolerability of novel combination chemotherapy, consisting of @entity2600 , high-dose 24-h continuous intravenous infusion of @entity10049 and @entity4181 in advanced previously untreated @entity14 . Thirty-eight @entity1 with advanced @entity14 were treated at Sylvester Comprehensive @entity5 Center, University of Miami, from 2000 to 2004, and received weekly intravenous infusion of @entity2600 at 110 mg/m with a combination of 120 mg/kg @entity10049 and 500 mg/m @entity4181 administered as a 24-h continuous intravenous infusion. The treatment cycle consisted of 4 weeks of consecutive therapy followed by 2 weeks of rest. Five (13%) @entity1 achieved complete response, 10 (26%) @entity1 achieved partial response, 17 (45%) @entity1 attained stable disease and six (16%) @entity1 progressed. The overall response rate was 39% in this study. This chemotherapy regiment was well tolerated; the most common grade 3 @entity137 were @entity1398 (16%), @entity417 (16%), @entity391 (24%), @entity294 (16%), and @entity8566 (26%). The median time to progression was 11.5 months (347.5 days) with 95% confidence intervals of 6.8-12.9 months (206-389 days). The time to progression ranged from 1.8 to 34 months. The median survival of the @entity1 in this trial was 31.28 months (952 days) with a confidence interval of 20.9-38.0 months (629-1141 days). Intravenous infusion of @entity10049 and @entity4181 is beneficial as first-line therapy in advanced @entity14 , demonstrating a prolonged time to progression and overall survival with acceptable tolerability and manageable @entity137 profile.

title: A phase II study of @entity2600 , high-dose 24-h continuous intravenous infusion of XXXX and @entity4181 (IFLUX) for advanced, previously untreated @entity14 .

entities_list: @entity4181 :: ('MESH:D002955', 'Chemical') :: ['leucovorin']

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities']

entities_list: @entity2600 :: ('MESH:C051890', 'Chemical') :: ['irinotecan']

entities_list: @entity5 :: ('MESH:D009369', 'Disease') :: ['Cancer']

entities_list: @entity294 :: ('MESH:D003967', 'Disease') :: ['diarrhea']

entities_list: @entity391 :: ('MESH:D014839', 'Disease') :: ['vomiting']

entities_list: @entity10049 :: ('MESH:D005467', 'Chemical') :: ['floxuridine']

entities_list: @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia']

entities_list: @entity8566 :: ('MESH:D060831', 'Disease') :: ['hand-and-foot syndrome']

entities_list: @entity14 :: ('MESH:D015179', 'Disease') :: ['colorectal cancer']

answer: @entity10049 :: (MESH:D005467,Chemical) :: ['floxuridine']


abstract: BACKGROUND: @entity1358 ( @entity1358 ) @entity1 receiving first-line @entity2240 typically survive >2 yr, with chronic treatment sometimes extending to >= 6 yr. OBJECTIVE: To analyze long-term safety with @entity2240 in @entity1358 @entity1 . DESIGN, SETTING, AND @entity1 : Data were pooled from 5739 @entity1 in nine trials, comprising seven phase II studies, a phase III study, and an expanded-access trial in various treatment settings (e.g., cytokine refractory or treatment-na  ve). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Interval and cumulative time-period analyses evaluated the incidence of treatment-related adverse events (TRAEs) for up to 6 yr, in the overall population and in those with long-term (>= 2 yr) @entity2240 treatment. RESULTS AND LIMITATIONS: Among long-term @entity1 (n=807), most TRAEs occurred initially in the first year and then decreased in frequency; TRAEs following this pattern included decreased appetite, @entity294 , @entity2342 , @entity2210 , @entity1295 , @entity101 , @entity32 , @entity390 , and @entity3136 . However, @entity1375 increased by interval analysis from 6% at 0-<6 mo to 42% at 5-<6 yr and by cumulative analysis from 14% at 0-<1 yr to 36% over 6 yr. Grade 3/4 TRAEs in long-term @entity1 peaked during the first year and then steadily decreased. The overall population displayed only minor differences from long-term @entity1 , with no clinically significant differences between grade >= 3 TRAE profiles (<5% difference in incidence rates at all intervals). Limitations included retrospective design, assessment variability, lack of pharmacokinetic data, and absence of baseline characteristics for long-term @entity1 . CONCLUSIONS: Prolonged @entity2240 was not associated with new types or increased severity of TRAEs. Except @entity1375 , @entity137 was not cumulative. @entity1 SUMMARY: More than 800 @entity1358 @entity1 received @entity2240 for between 2 and 6 yr without experiencing new or more severe treatment-related @entity137 . Clinicians may be able to prescribe chronic @entity2240 treatment for as long as @entity1 continue to derive clinical benefit, without untoward additional risk.

title: Long-term Safety of XXXX in @entity1358 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'PARTICIPANTS', 'PATIENT']

entities_list: @entity32 :: ('MESH:D007249', 'Disease') :: ['mucosal inflammation']

entities_list: @entity1375 :: ('MESH:D007037', 'Disease') :: ['hypothyroidism']

entities_list: @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity']

entities_list: @entity101 :: ('MESH:D006973', 'Disease') :: ['hypertension']

entities_list: @entity2240 :: ('MESH:C473478', 'Chemical') :: ['sunitinib']

entities_list: @entity3136 :: ('MESH:D013280', 'Disease') :: ['stomatitis']

entities_list: @entity1358 :: ('MESH:D002292', 'Disease') :: ['mRCC', 'Metastatic renal cell carcinoma']

entities_list: @entity2210 :: ('MESH:D004415', 'Disease') :: ['dyspepsia']

entities_list: @entity2342 :: ('MESH:D004408', 'Disease') :: ['dysgeusia']

answer: @entity2240 :: (MESH:C473478,Chemical) :: ['Sunitinib']


abstract: OBJECTIVES: To evaluate the effects and safeness of combined hysterolaparoscopy on evaluation the causes of @entity249 . METHODS: This retrospective study was conducted at the Department of Gynecology (The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong, China) from January 2011 to April 2014. @entity1 aged 21-43 years with @entity249 were included in this study. The prevalence of different lesions was collected to analyze. RESULTS: 132 @entity249 @entity1 were included, 71 (53.8%) @entity1 had @entity249 and the rest 61 (46.2%) had secondary @entity249 . Laparoscopic abnormalites were more common than hysteroscopy abnormalites both in @entity249 group and secondary @entity249 group. @entity4134 (59.09 %) and @entity46 (29.55%) were the most common abnormalities in two groups. The most common intrauterine pathology was uterine @entity1127 and the most common uterine @entity600 was uterine septum in two groups. Out of 12 @entity1 having @entity600 uterus, only one was double uterus and double cervical with @entity8376 . There was no major surgical or anesthetic complication in any of our @entity1 , other than mild @entity490 . CONCLUSION: Hysterolaparoscopy is an effective and safe tool in comprehensive evaluation of @entity249 to diagnosis and treat the lesions of pelvic and uterus in the same time. Hysterolaparoscopy may be recommended as the first and final procedure for evaluation of @entity9814 .

title: Combined hysterolaparoscopy for the diagnosis of XXXX : a retrospective study of 132 @entity1 in china.

entities_list: @entity1 :: ('9606', 'Species') :: ['women', 'Patients', 'patients']

entities_list: @entity249 :: ('MESH:D007246', 'Disease') :: ['infertility', 'infertile', 'primary infertility']

entities_list: @entity600 :: ('MESH:D000014', 'Disease') :: ['malformation']

entities_list: @entity46 :: ('MESH:D004715', 'Disease') :: ['endometriosis']

entities_list: @entity9814 :: ('MESH:D007247', 'Disease') :: ['female infertility']

entities_list: @entity8376 :: ('MESH:D014625', 'Disease') :: ['double vagina']

entities_list: @entity4134 :: ('MESH:D000292', 'Disease') :: ['Pelvic inflammatory disease']

entities_list: @entity490 :: ('MESH:D015746', 'Disease') :: ['abdominal pain']

answer: @entity9814 :: (MESH:D007247,Disease) :: ['female infertility']


abstract: INTRODUCTION: Computed Tomography Angiography (CTA) is being used to identify @entity438 ( @entity438 ) in @entity1 with findings such as skull fracture and @entity932 on initial Computed Tomography (CT) scans after blunt @entity131 ( @entity131 ). However, the incidence of @entity438 in @entity1 with blunt @entity131 is unknown. The aim of this study is to report the incidence of @entity438 in @entity1 with blunt @entity131 and to assess the utility of CTA in detecting these lesions. METHODS: A 10-year retrospective study (2003-2012) was performed at a Level 1 @entity130 centre. All @entity1 with blunt @entity131 who had an initial non-contrasted head CT scan and a follow-up head CTA were included. Head CTAs were then reviewed by a single investigator and TICAs were identified. The primary outcome measure was incidence of @entity438 in blunt @entity131 . RESULTS: A total of 10 257 @entity1 with blunt @entity131 were identified, out of which 459 @entity1 were included in the analysis. Mean age was 47.3        22.5, the majority were male (65.1%) and median ISS was 16 [9-25]. Thirty-six @entity1 (7.8%) had @entity438 , of which three @entity1 (0.65%) had TICAs. CONCLUSION: The incidence of @entity438 was exceedingly low (0.65%) over 10-years. This study adds to the growing literature questioning the empiric use of CTA for detecting @entity1317 in @entity1 with blunt @entity131 .

title: Traumatic XXXX in @entity130 .

entities_list: @entity1 :: ('9606', 'Species') :: ['patients']

entities_list: @entity131 :: ('MESH:D001930', 'Disease') :: ['TBI', 'traumatic brain injury']

entities_list: @entity932 :: ('MESH:D020300', 'Disease') :: ['intracranial haemorrhage']

entities_list: @entity1317 :: ('MESH:D057772', 'Disease') :: ['vascular injuries']

entities_list: @entity438 :: ('MESH:D002532', 'Disease') :: ['intracranial aneurysm', 'TICA', 'traumatic intracranial aneurysms', 'traumatic intracranial aneurysm']

answer: @entity438 :: (MESH:D002532,Disease) :: ['intracranial aneurysm']


abstract: BACKGROUND: The NCIC CTG LY.12 study showed that @entity136 , @entity619 , and @entity900 (GDP) were noninferior to @entity619 , @entity2592 , and @entity900 (DHAP) in @entity1 with relapsed or refractory aggressive @entity706 prior to autologous stem cell transplantation. We conducted an economic evaluation from the perspective of the Canadian public healthcare system based on trial data. METHODS: The primary outcome was an incremental cost utility analysis comparing costs and benefits associated with GDP vs DHAP. Resource utilization data were collected from 519 Canadian @entity1 in the trial. Costs were presented in 2012 Canadian dollars and disaggregated to highlight the major cost drivers of care. Benefit was measured as quality-adjusted life-years (QALYs) based on utilities translated from prospectively collected quality-of-life data. All statistical tests were two-sided. RESULTS: The mean overall costs of treatment per @entity1 in the GDP and DHAP arms were  19 961 (95% confidence interval (CI) =  17 286 to  24 565) and  34 425 (95% CI =  31 901 to  39 520), respectively, with an incremental difference in direct medical costs of  14 464 per @entity1 in favor of GDP (P < .001). The predominant cost driver for both treatment arms was related to hospitalizations. The mean discounted quality-adjusted overall survival with GDP was 0.161 QALYs and 0.152 QALYs for DHAP (difference = 0.01 QALYs, P = .146). In probabilistic sensitivity analysis, GDP was associated with both cost savings and improved quality-adjusted outcomes compared with DHAP in 92.6% of cost-pair simulations. CONCLUSIONS: GDP was associated with both lower costs and similar quality-adjusted outcomes compared with DHAP in @entity1 with relapsed or @entity706 . Considering both costs and outcomes, GDP was the dominant therapy.

title: @entity136 / @entity619 / @entity900 vs @entity2592 / XXXX / @entity900 for Relapsed or Refractory Aggressive-Histology Lymphoma: Cost-Utility Analysis of NCIC CTG LY.12.

entities_list: @entity1 :: ('9606', 'Species') :: ['patients', 'patient']

entities_list: @entity706 :: ('MESH:D008223', 'Disease') :: ['refractory lymphoma', 'histology lymphoma']

entities_list: @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin']

entities_list: @entity2592 :: ('MESH:D003561', 'Chemical') :: ['cytarabine']

entities_list: @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']

entities_list: @entity136 :: ('MESH:C056507', 'Chemical') :: ['gemcitabine']

answer: @entity619 :: (MESH:D003907,Chemical) :: ['Dexamethasone']


abstract: A High Performance Liquid Chromatography (HPLC) method was developed and validated to quantify @entity969 (non-reducing sugar), @entity413 , and @entity948 (reducing @entity3363 ) in raw tubers of @entity415 Group Phureja. Chromatographic analysis was performed using an AMINEX HPX 87H column, at 18  C, linked to a refraction index detector, at 35  C. The eluent was 10mM @entity8316 . The conditions established for the method provided an optimum separation of @entity3363 , @entity1792 , and @entity5910 , with resolution values higher or equal to one. Among the four sugar extraction methods tested, the double 50% (v/v) aqueous @entity1042 extraction gave the highest level of analytes. Recovery of this extraction method ranged between 94.14 and 99.77%. The HPLC method was validated for repeatability, reproducibility, linearity, and limits of detection, and quantification. Relative standard deviation was found to be lower than five, when testing repeatability and reproducibility, which is suitable considering a range of acceptability from 5.3 to 7.3. Additionally, the regression analyses supported the method linearity in a range of quantification from 3 to 100mg/L with regression coefficients values greater than 0.998 for the three analytes. Limits of detection were 3.0mg/L for the three @entity3363 and limits of quantification were 2.0mg/L for @entity969 and 3.0mg/L for @entity413 and @entity948 . Four Colombian commercial cultivars (Criolla Guane  a, Criolla Paisa, Criolla Galeras, and Criolla Colombia) and five landrace accessions from the Colombian Core Collection of Group Phureja were grown in the district of Usme (Bogot  ) fields to analyze their sugar contents. @entity969 , @entity413 , and @entity948 contents were found ranging from 0.93 to 3.11g/100g tuber dried weight (DW), from 0.25 to 4.53g/100g tuber DW, and from 0.10 to 1.49g/100g tuber DW, respectively. Therefore, a high range in the variability of sugar contents was found among genotypes. However, the variability was low among technical replicates of the same genotype, revealing an accurate quantification of @entity3363 in Group Phureja. This method can be used to assess the amount of reducing and non-reducing @entity3363 accumulation in @entity415 germplasm.

title: Development and validation of a liquid chromatographic method to quantify @entity969 , @entity413 , and XXXX in tubers of @entity415 Group Phureja.

entities_list: @entity8316 :: ('MESH:C033158', 'Chemical') :: ['sulfuric acid']

entities_list: @entity1792 :: ('MESH:D019343', 'Chemical') :: ['citric acid']

entities_list: @entity948 :: ('MESH:D005632', 'Chemical') :: ['fructose']

entities_list: @entity1042 :: ('MESH:D000432', 'Chemical') :: ['methanol']

entities_list: @entity5910 :: ('MESH:C030298', 'Chemical') :: ['malic acid']

entities_list: @entity969 :: ('MESH:D013395', 'Chemical') :: ['Sucrose', 'sucrose']

entities_list: @entity415 :: ('4113', 'Species') :: ['potato', 'Solanum tuberosum']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose']

answer: @entity948 :: (MESH:D005632,Chemical) :: ['fructose']


abstract: @entity195 ( @entity195 ) is the most common form of @entity303 , characterized by progressive @entity73 . One of the pathological hallmarks of @entity195 is the formation of neurofibrillary tangles composed of @entity854 , but global deregulation of protein phosphorylation in @entity195 is not well analyzed. Here, we report a pilot investigation of @entity195 phosphoproteome by @entity6701 enrichment coupled with high resolution LC-MS/MS. During the optimization of the enrichment method, we found that @entity4613 ion at a low concentration (e.g. 1 mM) worked efficiently as a nonphosphopeptide competitor to reduce background. The procedure was further tuned with respect to peptide-to-bead ratio, phosphopeptide recovery, and purity. Using this refined method and 9 h LC-MS/MS, we analyzed phosphoproteome in one milligram of digested @entity195 brain lysate, identifying 5243 phosphopeptides containing 3715 nonredundant phosphosites on 1455 proteins, including 31 phosphosites on the tau protein. This modified enrichment method is simple and highly efficient. The @entity195 case study demonstrates its feasibility of dissecting phosphoproteome in a limited amount of postmortem @entity1 brain. All MS data have been deposited in the ProteomeXchange with identifier PXD001180 (http://proteomecentral.proteomexchange.org/dataset/PXD001180).

title: Refined phosphopeptide enrichment by XXXX additive and the analysis of @entity1 brain phosphoproteome.

entities_list: @entity303 :: ('MESH:D003704', 'Disease') :: ['dementia']

entities_list: @entity73 :: ('MESH:D003072', 'Disease') :: ['loss of cognitive function']

entities_list: @entity854 :: ('MESH:D018376', 'Disease') :: ['abnormally hyperphosphorylated tau protein']

entities_list: @entity195 :: ('MESH:D000544', 'Disease') :: ['AD', "Alzheimer's disease"]

entities_list: @entity6701 :: ('MESH:C009495', 'Chemical') :: ['titanium dioxide']

answer: @entity4613 :: (D010710,Chemical) :: ['phosphate']


abstract: UNASSIGNED: Islet microencapsulation is an attractive strategy for the minimization or avoidance of life-long immunosuppression after transplantation. However, the clinical implementation of this technique is currently limited by incomplete biocompatibility. Thus, the aim of the present study was to demonstrate the improved biocompatibility of @entity3446 -containing @entity968 ( @entity37714 - @entity970 )-coating on alginate microcapsules containing xenogeneic islets. The @entity37714 - @entity970 -coating on the alginate layer was observed using scanning electron microscopy (SEM) and the molecular cut-off weight of the microcapsules was approximately 70 kDa. The viabilities of the alginate-encapsulated and @entity37714 -PEG-coated alginate-encapsulated islets were lower than the viability of the naked islets just after encapsulation, but these the differences diminished over time in culture dishes. @entity37714 -PEG-coating on the alginate capsules effectively decreased the proliferation of macrophage cells compared to the non-coating and alginate coating of xenogeneic pancreas tissues. @entity413 -stimulated insulin secretion did not significantly differ among the groups prior to transplantation. The random blood @entity413 levels of @entity6 @entity19 significantly improved following the transplantation of alginate-encapsulated and @entity37714 -PEG-coated alginate-encapsulated islets, but there were no significant differences between these two groups. However, there was a significant decrease in the number of microcapsules with fibrotic cell infiltration in the @entity37714 - @entity970 -coated alginate microcapsule group compared to the alginate microcapsule group. In conclusion, @entity37714 -PEG-coating might be an effective technique with which to improve the biocompatibility of microcapsules containing xenogeneic islets. Copyright    2015 John Wiley _ Sons, Ltd.

title: Antifibrotic effect of @entity3446 containing XXXX -coated alginate microcapsule in islet xenotransplantation.

entities_list: @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic']

entities_list: @entity3446 :: ('MESH:D020123', 'Chemical') :: ['rapamycin']

entities_list: @entity413 :: ('MESH:D005947', 'Chemical') :: ['glucose', 'Glucose']

entities_list: @entity968 :: ('MESH:D011092', 'Chemical') :: ['polyethylene glycol']

answer: @entity968 :: (MESH:D011092,Chemical) :: ['polyethylene glycol']